NCT02663700View on ClinicalTrials.gov

Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

April 7, 2016

Primary Completion Date

December 17, 2018

Study Completion Date

December 17, 2018

Conditions
Plasmodium Falciparum Infection
Interventions
DRUG

Artesunate

Four tablets of 50mg each, totaling 200mg will be given in a single calendar day

BIOLOGICAL

PfSPZ Vaccine

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

OTHER

Placebo

Placebo

Trial Locations (1)

Unknown

Centre National de Recherche et de Formation sur le Paludisme - Research and Training, Ouagadougou

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02663700 - Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso | Biotech Hunter | Biotech Hunter